Premium
SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: a TRIAL OF THE ECOG‐ACRIN CANCER RESEARCH GROUP (E4412)
Author(s) -
Diefenbach C.S.,
Hong F.,
David K.,
Cohen J.,
Roberston M.,
Advani R.,
Palmisano N.,
Ambinder R.,
Kahl B.,
Ansell S.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_72
Subject(s) - brentuximab vedotin , nivolumab , medicine , oncology , ipilimumab , cohort , adverse effect , lung cancer , refractory (planetary science) , lymphoma , cancer , immunotherapy , hodgkin lymphoma , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom